Abstract
Porphyrias are metabolic disorders of the heme biosynthesis. Clinically, they can be differentiated into acute and non-acute porphyrias. The symptomatic phase of acute hepatic porphyrias is characterized by overproduction of neurotoxic porphyrin precursors and porphyrins. Acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), and Doss porphyria (ALSDP) belong to this group of metabolic disorders. The clinical presentation of the acute hepatic porphyria syndrome includes abdominal, psychiatric, neurological, and cardiovascular symptoms. The diagnosis is based on an at least tenfold increased urinary excretion of porphobilinogen (apart from Doss porphyria and lead intoxication). Besides symptomatic therapy with non-porphyrinogenic drugs, electrolyte compensation, and intensive monitoring, intravenous administration of glucose and heme arginate is established for treatment. Among the non-acute types like porphyria cutanea tarda, erythropoietic protoporphyria, and congenital erythropoietic porphyria, the accumulated porphyrins cause photosensitivity of the skin and in some cases severe liver damage. X-linked protoporphyria (XLPP) represents a new type of protoporphyria, with 5-aminolevulinic acid synthase 2 gain of function leading to high concentrations of free protoporphyrin IX. The location of the deficient enzyme within the heme biosynthetic pathway determines the pattern of the accumulated porphyrins. The cDNA of all enzymes of heme biosynthesis have been characterized, and mutations responsible for any of the porphyrias have been described. Besides light protection, there are different therapies depending on the type of non-acute porphyria. Ultimately, liver transplantation may be considered in therapy-resistant cases of acute hepatic porphyrias and bone marrow transplantation in severe cases of erythropoietic porphyrias.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ (2005) Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 142:439–450
Bonkovsky HL (1993) Advances in understanding and treating ‘the little imitator’, acute porphyria. Gastroenterology 105:590–594
Bonkovsky HL, Guo JT, Hou W, Li T, Narang T, Thapar M (2013) Porphyrin and heme metabolism and the porphyrias. Compr Physiol 3:365–401
Bonkowsky HL, Tschudy DP, Collins A, Doherty J, Bossenmaier I, Cardinal R, Watson CJ (1971) Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc Natl Acad Sci U S A 68:2725–2729
Doss M, Verspohl F (1981) The “glucose effect” in acute hepatic porphyrias and in experimental porphyria. Klin Wochenschr 59:727–735
Doss M, von Tiepermann R, Schneider J, Schmid H (1979) New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr 57:1123–1127
Handschin C, Lin J, Rhee J, Peyer AK, Chin S, Wu PH, Meyer UA, Spiegelman BM (2005) Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122:505–515
Kostler E, Wollina U (2005) Therapy of porphyria cutanea tarda. Expert Opin Pharmacother 6:377–383
Kühnel A, Groß U, Doss MO (2002) Porphyrien. In: Schmailzl KJG, Hachelöer BJ (eds) Schwangerschaft und Krankheit. Blackwell Verlag, Berlin/Wien, pp S440–S453
Puy H, Gouya L, Deybach JC (2010) Porphyrias. Lancet 375:924–937
Seth AK, Badminton MN, Mirza D, Russell S, Elias E (2007) Liver transplantation for porphyria: who, when, and how? Liver Transpl 13:1219–1227
Stölzel U, Doss M (2009) Porphyrias. In: Dancygier H (ed) Clinical hepatology, principles and practice of hepatobiliary diseases, vol 2. Springer, Berlin, pp 1077–1092
Stölzel U, Doss MO, Dissmann T, Cervós-Navarro J, Riecken EO (1987) Gastroenterologic and neurologic manifestations in acute intermittent porphyria. Med Klin (Munich) 82:520–525
Stölzel U, Köstler E, Koszka C, Stöffler-Meilicke M, Schuppan D, Somasundaram R, Doss MO, Habermehl KO, Riecken EO (1995) Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 21:1500–1503
Stölzel U, Köstler E, Schuppan D, Richter M, Wollina U, Doss MO, Wittekind C, Tannapfel A (2003) Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 139:309–313
Stölzel U, Brosche C, Koszka C, Stauch T, Teubner A, Doss MO (2009) Safe and probably safe drugs in acute porphyria. Cell Mol Biol 55:147–151
Wahlin S, Aschan J, Björnstedt M, Broomé U, Harper P (2007) Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 46:174–179
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Stölzel, U., Stauch, T., Doss, M.O. (2014). Heme Synthesis Defects and Porphyrias. In: Blau, N., Duran, M., Gibson, K., Dionisi Vici, C. (eds) Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40337-8_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-40337-8_33
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40336-1
Online ISBN: 978-3-642-40337-8
eBook Packages: MedicineMedicine (R0)